StreetAlpha.app
Home › Stocks › CUE

Cue Biopharma, Inc. (CUE)

$4.15
▼ −7.78%
LAST CLOSE · NOV 20

Cue Biopharma develops injectable treatments that target specific immune cells for autoimmune and inflammatory diseases. It last closed at $4.15 on Nov 20, down 7.78% on the day. The next earnings report for CUE is expected around Mon, Mar 15, 2027, after the close. For the quarter ended Sep 2026, CUE reported EPS of -$4.74 on revenue of $132,000, with revenue down 93.9% from a year ago. Over its last 8 reports the stock moved an average of 19.8% the session after earnings. Over the last 12 months CUE insiders bought $100K of stock on the open market and sold $2.4M, according to SEC Form 4 filings.

AI Auto Pilots
Is CUE in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold CUE.

Key Stats

Last 12 months
Results
Revenue
$35.6M
+401.9% vs a year ago
Net income
−$206.7M
−579.9% margin
EPS (diluted)
−$19.61
Free cash flow
−$51.2M
−143.7% margin
Valuation
Market cap
$34.7M
8.4M shares
P/E
–
No P/E while losing money
Price to sales
1.0
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$57.9M
At Sep 30
Shareholder equity
$38.4M
Shares outstanding
8.4M
At Nov 13
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $14.9M$14.9MFY2021FY2022: $1.2M$1.2MFY2022FY2023: $5.5M$5.5MFY2023FY2024: $9.3M$9.3MFY2024FY2025: $27.5M$27.5MFY2025

From CUE's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 16). Last 12 months adds up the four latest quarters.

Next report
Mar 15
Estimated date · After the close
Reported EPS
-$4.74
Quarter ended Sep 2026
Year ago EPS
-$2.22
Same quarter last year
Revenue
$132,000
−93.9% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.10Dec '24Mar 2025: -$4.95Mar '25Jun 2025: -$2.67Jun '25Sep 2025: -$2.22Sep '25Dec 2025: $9.09Dec '25Mar 2026: -$1.08Mar '26Jun 2026: -$24.14Jun '26Sep 2026: -$4.74Sep '26Latest -$4.74
Revenue by quarter
Dec 2024: $1.6MDec '24Mar 2025: $421,000Mar '25Jun 2025: $3.0MJun '25Sep 2025: $2.1MSep '25Dec 2025: $21.9MDec '25Mar 2026: $5.7MMar '26Jun 2026: $7.9MJun '26Sep 2026: $132,000Sep '26Latest $132,000
How CUE moved after its last 8 reports
Average move the session after a report ±19.8%
Nov 16, 2026After the close−79.9%
Aug 14, 2026After the close−19.2%
Mar 16, 2026After the close−12.8%
Nov 12, 2025After the close−7.2%
Aug 12, 2025After the close+2.6%
May 12, 2025After the close+2.3%
Mar 31, 2025After the close−17.7%
Nov 14, 2024After the close−17.0%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on CUEStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on CUE
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on CUE

Technical Analysis

CUE · as of the Nov 20 close · updated each morning
Downtrend, oversold

The stock is 284% below its 20 day and 422% below its 50 day average. It is 417% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 25), oversold. The nearest support is the Pivot S1 at $3.83, and the nearest resistance the Pivot at $4.37.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 65.6%/day
Key levels
$45.5052 week high+996.4%
$25.47100 day average+513.7%
$21.6550 day average+421.7%
$21.48200 day average+417.6%
$19.54Swing high (Oct 21)+370.8%
$15.9320 day average+283.9%
$4.68Pivot R1+12.8%
$4.37Pivot+5.3%
$4.15Last close
$3.83Pivot S1−7.7%
$2.8352 week low−31.8%
$2.83Swing low (Nov 17)−31.8%
Indicators
RSI (14)24.72Oversold below 30Oversold
MACD-4.32Below its signal lineBearish
Stochastic8.9Near the bottom of its rangeOversold
ADX (14)26.1Trending down
Williams %R-92.8Oversold below −80, overbought above −20Oversold
CCI (20)-168.0Oversold below −100, overbought above 100Oversold
Rate of change−77.8%Change over 10 sessionsBearish
ATR (14)$2.72Typical daily range, 65.5% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for CUE

What happened before

See how CUE did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow CUE usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How CUE has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2018.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for CUEHow many large options trades hit CUE, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

CUE Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲34 buying vs 18 selling
  • ▲Held by funds +36.4 pts
  • ▲Funds holding +8
  • ▼Superinvestors: 1 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding5850+16.0%
In funds' top 1012−50.0%
Held by funds56.0%19.6%+36.4 pts
New / increased17 / 1748 / 0−29.2%
Reduced / sold out9 / 91 / 54−67.3%
Put/call ratio–0.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See CUE institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

CUE Insider Trading

All filings →
Insider trading · 12 months
Insiders are net sellers
Bought$100K1 buy · 1 insider
Sold$2.4M6 sales · 3 insiders
2025-12 bought $100K2026-08 sold $2.0M2026-10 sold $389KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Oct 12Sumita RayChief Legal Compliance OfficerSale1,844$28.05$52K
Oct 12Shao-Lee LinCEOSale11,087$27.55$305K
Oct 12Michael Vincent MeluzioVP, Prin. Accounting OfficerSale1,144$28.05$32K
Aug 13Sumita RayChief Legal Compliance OfficerSale8,829$30.09$266K
Aug 13Michael Vincent MeluzioVP, Prin. Accounting OfficerSale5,628$30.09$169K
Aug 13Shao-Lee LinCEOSale58,258$27.58$1.6M
Every insider buy and sale for CUE over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See CUE insider trades →

From SEC Form 4 filings by CUE's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CUE is in one of them and how their past CUE trades turned out.

CUE in the AI portfolios
Loading…

CUE News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered CUE in an article yet. Here's the latest on the wider market.

CUE in the news

About Cue Biopharma

Cue Biopharma is a biopharmaceutical company based in Somerville, Massachusetts, that is developing injectable treatments for autoimmune and inflammatory diseases. Its drug candidates are designed to act on specific immune cells, aiming to calm harmful immune responses while leaving the rest of the immune system largely intact. Its lead program is still in preclinical work, and some of its other candidates have been licensed to outside drugmakers. The company's target patients are people living with these conditions.

Headquarters
Somerville, MA